Compass Pathways (NASDAQ: CMPS) deepened its financial losses to $155.1 million in 2024 as the company nears a big milestone for its experimental psilocybin therapy, with pivotal clinical trial results expected by midyear.
The drug maker reported Thursday that its losses widened from $118.5 million in 2023, though loss per share…
Please login to read all 271 words.
